KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Payables: 2011-2025

Historic Payables for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to $108.6 million.

  • Supernus Pharmaceuticals' Payables rose 43.28% to $108.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $339.6 million, marking a year-over-year increase of 4.69%. This contributed to the annual value of $76.4 million for FY2024, which is 4.04% down from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Payables stood at $108.6 million, which was up 39.71% from $77.7 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Payables high stood at $498.3 million for Q4 2022, and its period low was $70.1 million during Q1 2021.
  • Moreover, its 3-year median value for Payables was $79.6 million (2023), whereas its average is $120.3 million.
  • The largest annual percentage gain for Supernus Pharmaceuticals' Payables in the last 5 years was 456.67% (2023), contrasted with its biggest fall of 84.03% (2023).
  • Over the past 5 years, Supernus Pharmaceuticals' Payables (Quarterly) stood at $117.7 million in 2021, then surged by 323.43% to $498.3 million in 2022, then tumbled by 84.03% to $79.6 million in 2023, then dropped by 4.04% to $76.4 million in 2024, then skyrocketed by 43.28% to $108.6 million in 2025.
  • Its Payables stands at $108.6 million for Q3 2025, versus $77.7 million for Q2 2025 and $76.9 million for Q1 2025.